

Supplementary material

Comparison of propensity score methods and covariate adjustment – a practical evaluation in four cardiovascular studies

Table of Contents

Supplementary tables

Table S1: Results from paired and unpaired analyses following propensity score matching

Table S2: Propensity score model for CHARM

Table S3: Propensity score model for ADAPT-DES

Table S4: Propensity score model for THIN

Table S5: Propensity score model for PROMETHEUS

Table S6: Covariate adjustment for CHARM

Table S7: Covariate adjustment for ADAPT-DES

Table S8: Covariate adjustment for THIN

Table S9: Covariate adjustment for PROMETHEUS

Table S10: Events per stratum in ADAPT-DES

Supplementary figures

Figure S1: CHARM results with and without trimming

Figure S2: ADAPT-DES results with and without trimming

Figure S3: THIN results with and without trimming

Figure S4: PROMETHEUS results with and without trimming

	Control		Treated		Hazard ratio (95% CI) from unpaired analysis	Hazard ratio from paired analysis
	Matched, N(%)	Unmatched, N(%)	Matched, N(%)	Unmatched, N(%)		
CHARM	3238 (95.3%)	158 (4.7%)	3238 (77.0%)	965 (23.0%)	0.71 (0.65 to 0.79)	0.72 (0.65 to 0.79)
ADAPT-DES	3289 (66.7%)	1641 (33.3%)	3289 (90.1%)	361 (9.9%)	2.07 (1.12 to 3.84)	2.12 (1.14 to 3.93)
THIN	3899 (25.0%)	11688 (75.0%)	3899 (97.1%)	118 (2.9%)	0.84 (0.80 to 0.89)	0.84 (0.80 to 0.89)
PROMETHEUS	21457 (35.2%)	39464 (64.8%)	21457 (69.6%)	9354 (30.4%)	0.85 (0.71 to 1.02)	0.85 (0.70 to 1.02)

Supplementary table S1: Results from paired and unpaired analyses following propensity score matching

Results from paired analyses were calculated by fitting a Cox-proportional hazards model which included a frailty term specific to each matched pair. Results from unpaired analysis used the same matched pairs data but ignored matching in the analysis.

Variable	Effect	SE	p
(Intercept)	2.131	0.269	<0.00001
Candesartan	-0.010	0.047	0.83812
NYHA classification	-0.118	0.047	0.01247
Age	-0.025	0.002	<0.00001
Ejection Fraction (per 5% decrease below 45)	-0.021	0.013	0.11571
Current Smoker	-0.248	0.069	0.00031
Diabetes Mellitus	0.417	0.115	0.00030
Dependent oedema	0.117	0.058	0.04440
Mitral regurgitation	-0.006	0.063	0.92960
Previous myocardial infarction	0.347	0.049	<0.00001
Previous atrial fibrillation	-0.188	0.055	0.00059
Diabetes: Insulin Treated	-0.330	0.136	0.01530
Oral therapy Treated Diabetes Mellitus	-0.361	0.128	0.00474
CHF time: <6 months	-0.069	0.069	0.31478
Diagnosis of CHF over 2 years ago	-0.141	0.057	0.01260
Cardiomegaly	-0.091	0.058	0.11364
Pulmonary crackles	-0.307	0.065	<0.00001
Sex: Female	-0.086	0.053	0.10424
BMI	0.000	0.005	0.94373

Supplementary table S2. Propensity score model for CHARM.

Propensity score methods versus covariate adjustment – Supplements

Variable	Log odds ratio	SE	p
(Intercept)	-3.45082	0.24710	<0.00001
Diabetes Mellitus	0.25824	0.07371	0.00046
Insulin for Diabetes Mellitus	-0.04669	0.09691	0.63000
Medications: ACE	-0.03633	0.05228	0.48712
Medications: ARB	0.04412	0.06922	0.52387
Medications: STATIN	-0.04014	0.06158	0.51458
Medications: NIACIN	-0.20872	0.13185	0.11342
Medications: FIBRICACID	0.03700	0.12417	0.76572
Medications: BETABLOCKER	0.08912	0.05920	0.13223
Medications: CALCIUMBLOCKER	0.09713	0.05791	0.09351
Medications: COUMADIN	-0.05496	0.11613	0.63599
Medications: INSULIN	0.28871	0.08570	0.00075
Medications: ORALHYPOGLYCEM	0.30241	0.07926	0.00014
Medications: NSAID	0.15381	0.10730	0.15173
Medications: COX2INHIBITOR	-0.00559	0.27774	0.98395
Medications: DIGOXIN	0.19467	0.16731	0.24463
Medications: OANTIHYPERTENS	0.14405	0.07322	0.04914
Medications: IVPRESSOR	-0.19267	0.32787	0.55678
Medications: CILOSTAZOL	-0.85601	0.34331	0.01265
Medications: AMIODARONE	0.32026	0.18739	0.08744
Medications: ATROPINE	0.73175	0.23639	0.00196
Medications: PPINHIBITORS	0.31447	0.05077	<0.00001
Medications: DIURETIC	-0.04058	0.05182	0.43364
Medications: RETAVASE	0.98349	0.93488	0.29280
Medications: TPA	-0.48316	0.44439	0.27693
Medications: TNK	-0.10757	0.56308	0.84850
Medications: OTHER	0.05748	0.04749	0.22609
Ever smoked	0.01545	0.04675	0.74110
INHOSP_TIMI_MAJOR	0.40837	0.69152	0.55483
Patient race: Asian Pacific	0.35033	0.29395	0.23334
Patient race: Caucasian	-0.37242	0.10262	0.00028
Patient race: Hispanic	-0.26806	0.18034	0.13717
Patient race: Multi Racial	-11.34682	134.73376	0.93288
Patient race: Native American	-0.40933	0.33615	0.22333
Patient race: Other	0.29120	0.37144	0.43305
Patient race: Unknown	-0.38279	0.17778	0.03131
Dialysis	0.29768	0.18983	0.11686
Renal insufficiency	0.04835	0.09170	0.59796
BMI	0.05776	0.00439	<0.00001
Age	0.02194	0.00232	<0.00001

Supplementary table S3. Propensity score model for ADAPT-DES.

Variable	Log odds ratio	SE	p
(Intercept)	-0.27370	0.09411	0.00363
BMI category 20-25	0.56897	0.05244	<0.00001
BMI category >25	0.49474	0.05147	<0.00001
BMI category missing	0.47542	0.06017	<0.00001
Age	-0.05568	0.00095	<0.00001
Sex	0.54676	0.01956	<0.00001
Alcohol status: ex-drinker	0.26728	0.08925	0.00275
Alcohol status: current drinker unknown	0.91915	0.04738	<0.00001
Alcohol status: rare drinker <2u/d	0.53369	0.02682	<0.00001
Alcohol status: moderate drinker 3-6u/d	1.09687	0.03465	<0.00001
Alcohol status: excessive drinker >6u/d	1.41222	0.06231	<0.00001
Alcohol status: drinking status unknown	0.57149	0.04581	<0.00001
Smoking status: ex	0.06742	0.02313	0.00356
Smoking status: current	-0.03077	0.02341	0.18871
Smoking status: unknown	-0.26012	0.08480	0.00216
Diabetes	0.23856	0.02296	<0.00001
Atrial fibrillation	-0.46167	0.03796	<0.00001
Heart failure	-0.09070	0.03247	0.00522
HRT (within 1 year)	-0.07853	0.04152	0.05858
Thyroid disease	-0.04904	0.03574	0.16994
Oral steroid (within 6 months)	-0.10218	0.06249	0.10204
Inhaled steroid (within 6 months)	-0.02495	0.03273	0.44588
Antipsychotics (within 6 months)	-0.29084	0.07447	0.00009
Antidepressants (within 6 months)	-0.09165	0.02779	0.00098
Townsend	-0.04142	0.00547	<0.00001
Drug prescriptions rate	-0.11655	0.00784	<0.00001
Renal disease (within 6 months)	0.04396	0.07183	0.54050
Fibrates (within 3 months)	-0.56939	0.09295	<0.00001
Nonstatin/fibrate lipid lowerers	0.14268	0.07844	0.06893
Consultations rate	0.11197	0.00568	<0.00001
Hyperlipidaemia	1.94410	0.02468	<0.00001
Hypertension	-0.37694	0.01873	<0.00001
Aspirin	0.84770	0.01830	<0.00001
Coronary heart disease	1.13339	0.03030	<0.00001
Cerebrovascular disease	0.01156	0.02641	0.66148
Peripheral vascular disease	0.02401	0.02864	0.40184
Beta-blocker	0.44074	0.01814	<0.00001
Nitrates	-0.29595	0.02085	<0.00001
Cytochrome	0.09675	0.02919	0.00092
Hepatic disease (within 6 months)	-0.67809	0.14009	<0.00001
Anticoagulants	0.05806	0.03368	0.08474
Ca ⁺⁺ blocker/K ⁺ activator	0.12242	0.01933	<0.00001
Other cardiovascular drugs	0.45201	0.02596	<0.00001
Cancer	-0.24206	0.03564	<0.00001
Diuretics	0.01281	0.02043	0.53067
Other circulatory disease	-0.15470	0.01875	<0.00001
Dementia	-1.00543	0.13855	<0.00001
Other atheroma	0.16813	0.10490	0.10898
Antihypertensives	0.50898	0.01983	<0.00001

Supplementary table S4. Propensity score model for THIN.

Variable	Effect	SE	p
(Intercept)	-4.34804	0.51542	<0.00001
CAD Presentation: Non-ST-elevation myocardial infarction	0.01245	0.04954	0.80150
CAD Presentation: ST-elevation myocardial infarction	0.12870	0.06356	0.04288
Diabetes mellitus, no insulin	0.15020	0.04926	0.00229
Diabetes mellitus, insulin	-0.05747	0.07035	0.41398
Age	0.15738	0.01557	<0.00001
Age squared	-0.00166	0.00013	<0.00001
Procedural Bivalirudin	0.23009	0.05832	0.00008
Smoker	-0.21857	0.04741	<0.00001
Sex: Female	-0.16126	0.04803	0.00079
Black/African American	-0.20356	0.07850	0.00951
Hypertension	-0.22115	0.05343	0.00003
Family history of CAD	-0.00026	0.04336	0.99523
Prior PAD	-0.07390	0.07425	0.31961
Prior CHF	-0.03199	0.05883	0.58654
Total stent length: 20-40	0.16352	0.04566	0.00034
Total stent length: 40+	0.27037	0.05312	<0.00001
Stent diameter	0.14372	0.02703	<0.00001
Hypercholesterolemia	-0.00770	0.05833	0.89498
Previous MI	-0.06613	0.05306	0.21264
eGFR using CKD-EPI	0.00360	0.00101	0.00035
Stent type: 1st generation	-0.04467	0.09111	0.62396
Stent type: Bare-metal stent	-0.45022	0.05828	<0.00001
BMI decile	0.01466	0.00729	0.04431
Hemoglobin	0.01755	0.01124	0.11853
Centre: Utah	0.15651	0.07422	0.03496
Centre: Aurora	0.05385	0.08863	0.54344
Centre: Pittsburgh	-1.37821	0.09216	<0.00001
Centre: Duke	-2.20494	0.12905	<0.00001
Centre: Cleveland	-2.45875	0.12647	<0.00001
Centre: Christiana	-0.44245	0.07241	<0.00001
Centre: Mount Sinai	-1.14579	0.07608	<0.00001
Glycoprotein IIb/IIIa	0.04322	0.05450	0.42778
Prior Cerebrovascular Disease	-0.66160	0.08542	<0.00001
Previous PCI	-0.30639	0.05637	<0.00001
Previous CABG	-0.32850	0.06757	<0.00001

Supplementary table S5. Propensity score model for PROMETHEUS.

Variable	Effect	Hazard ratio	SE	p
Treatment effect (beta-blockers)	-0.309	0.735	0.049	<0.00001
Candesartan	-0.098	0.906	0.047	0.03865
NYHA classification	0.311	1.365	0.049	<0.00001
Age	0.039	1.040	0.003	<0.00001
Ejection Fraction (per 5% decrease below 45)	0.157	1.170	0.013	<0.00001
Current Smoker	0.306	1.358	0.068	0.00001
Diabetes Mellitus	0.333	1.395	0.109	0.00223
Dependent oedema	0.240	1.271	0.055	0.00001
Mitral regurgitation	0.142	1.152	0.059	0.01663
Previous myocardial infarction	0.160	1.173	0.051	0.00165
Previous atrial fibrillation	0.132	1.141	0.053	0.01266
Diabetes: Insulin Treated	0.321	1.378	0.125	0.01013
Oral therapy Treated Diabetes Mellitus	0.110	1.117	0.119	0.35169
CHF time: <6 months	0.070	1.073	0.076	0.35518
Diagnosis of CHF over 2 years ago	0.187	1.206	0.059	0.00147
Cardiomegaly	0.319	1.376	0.053	<0.00001
Pulmonary crackles	0.232	1.261	0.060	0.00011
Sex: Female	-0.174	0.840	0.055	0.00159
BMI	-0.034	0.966	0.006	<0.00001

Supplementary table S6. Covariate adjustment for CHARM.

Variable	Effect	Hazard ratio	SE	p
Treatment effect	0.77428	2.16903	0.29548	0.00878
Age	-0.02988	0.97057	0.01469	0.04201
Sex: male	-0.18760	0.82895	0.31321	0.54919
Diabetes Mellitus	0.04345	1.04441	0.50460	0.93138
Insulin for Diabetes Mellitus	0.27323	1.31420	0.47298	0.56349
Medications: ACE	0.37740	1.45849	0.37497	0.31418
Medications: ARB	0.10700	1.11294	0.48925	0.82688
Medications: STATIN	0.47591	1.60948	0.47335	0.31470
Medications: NIACIN	0.04800	1.04917	0.74546	0.94866
Medications: FIBRICACID	-17.94914	<0.00001	0.20555	<0.00001
Medications: BETABLOCKER	0.09018	1.09437	0.42839	0.83328
Medications: CALCIUMBLOCKER	-0.15864	0.85331	0.35479	0.65478
Medications: COUMADIN	-0.18030	0.83502	0.67394	0.78906
Medications: INSULIN	0.51507	1.67375	0.49524	0.29832
Medications: ORALHYPOGLYCEM	0.23891	1.26986	0.41518	0.56499
Medications: NSAID	-1.27737	0.27877	1.03587	0.21752
Medications: COX2INHIBITOR	-17.12111	<0.00001	0.36297	<0.00001
Medications: DIGOXIN	-0.36048	0.69734	0.96243	0.70799
Medications: OANTIHYPERTENS	-0.43158	0.64948	0.46607	0.35444
Medications: IVPRESSOR	0.71949	2.05339	1.28035	0.57415
Medications: CILOSTAZOL	-17.81496	<0.00001	0.32030	<0.00001
Medications: AMIODARONE	1.82310	6.19103	0.53499	0.00066
Medications: ATROPINE	-17.50844	<0.00001	0.26826	<0.00001
Medications: PPINHIBITORS	0.37771	1.45894	0.28041	0.17799
Medications: DIURETIC	-0.20790	0.81229	0.30921	0.50135
Medications: RETAVASE	-17.53902	<0.00001	0.70987	<0.00001
Medications: TPA	-17.24371	<0.00001	0.38948	<0.00001
Medications: TNK	-17.98052	<0.00001	0.67122	<0.00001
Medications: OTHER	1.14257	3.13480	0.35034	0.00111
Ever smoked	0.67765	1.96925	0.31220	0.02996
INHOSP_TIMI_MAJOR	-18.29074	<0.00001	1.21248	<0.00001
Patient race: Asian Pacific	-17.76895	<0.00001	0.59366	<0.00001
Patient race: Caucasian	-0.28688	0.75060	0.48683	0.55568
Patient race: Hispanic	-17.91993	<0.00001	0.49207	<0.00001
Patient race: Multi Racial	-17.09200	<0.00001	1.01297	<0.00001
Patient race: Native American	-18.36642	<0.00001	0.54376	<0.00001
Patient race: Other	-17.96366	<0.00001	0.58303	<0.00001
Patient race: Unknown	-0.35475	0.70135	1.09867	0.74678
Dialysis	1.27997	3.59654	0.52342	0.01447
Renal insufficiency	0.23445	1.26421	0.41803	0.57491
BMI	0.01325	1.01334	0.02684	0.62142

Supplementary table S7. Covariate adjustment for ADAPT-DES.

Variable	Effect	Hazard ratio	SE	p
Treatment effect	-0.16176	0.85065	0.02096	<0.00001
Age	0.05969	1.06150	0.00108	<0.00001
Sex	-0.50158	0.60558	0.01816	<0.00001
BMI category 20-25	-0.43960	0.64429	0.03446	<0.00001
BMI category >25	-0.60996	0.54337	0.03355	<0.00001
BMI category missing	-0.01348	0.98661	0.03918	0.73075
Alcohol status: ex-drinker	-0.35321	0.70243	0.08573	0.00004
Alcohol status: current drinker unknown	-0.04309	0.95783	0.04464	0.33441
Alcohol status: rare drinker <2u/d	-0.14969	0.86097	0.02209	<0.00001
Alcohol status: moderate drinker 3-6u/d	-0.05753	0.94410	0.03209	0.07303
Alcohol status: excessive drinker >6u/d	0.07387	1.07667	0.06295	0.24060
Alcohol status: drinking status unknown	0.23960	1.27074	0.03440	<0.00001
Smoking status: ex	-0.39192	0.67576	0.02201	<0.00001
Smoking status: current	0.08064	1.08398	0.02136	0.00016
Smoking status: unknown	0.75780	2.13358	0.04529	<0.00001
Diabetes	0.32397	1.38260	0.01982	<0.00001
Atrial fibrillation	0.06143	1.06336	0.02837	0.03036
Heart failure	0.38263	1.46614	0.02380	<0.00001
HRT (within 1 year)	-0.36211	0.69620	0.06949	<0.00001
Thyroid disease	-0.05235	0.94899	0.03295	0.11206
Oral steroid (within 6 months)	0.31602	1.37166	0.04610	<0.00001
Inhaled steroid (within 6 months)	0.20432	1.22669	0.02613	<0.00001
Antipsychotics (within 6 months)	0.28859	1.33455	0.05060	<0.00001
Antidepressants (within 6 months)	0.08965	1.09379	0.02438	0.00024
Townsend	0.06561	1.06781	0.00507	<0.00001
Drug prescriptions rate	0.15059	1.16252	0.00752	<0.00001
Renal disease (within 6 months)	0.43128	1.53923	0.05446	<0.00001
Fibrates (within 3 months)	-0.16685	0.84632	0.09282	0.07224
Nonstatin/fibrate lipid lowerers	0.06004	1.06188	0.07463	0.42109
Consultations rate	-0.02145	0.97878	0.00515	0.00003
Hyperlipidaemia	-0.12286	0.88439	0.02787	0.00001
Hypertension	-0.01546	0.98466	0.01729	0.37139
Aspirin	-0.01674	0.98340	0.01675	0.31761
Coronary heart disease	0.16494	1.17932	0.02543	<0.00001
Cerebrovascular disease	0.26874	1.30831	0.02148	<0.00001
Peripheral vascular disease	0.30821	1.36099	0.02259	<0.00001
Beta-blocker	-0.14210	0.86754	0.01732	<0.00001
Nitrates	-0.03435	0.96623	0.02074	0.09767
Cytochrome	-0.00299	0.99702	0.02717	0.91245
Hepatic disease (within 6 months)	0.47778	1.61250	0.10021	<0.00001
Anticoagulants	0.07694	1.07998	0.02726	0.00477
Ca ⁺⁺ blocker/K ⁺ activator	-0.01972	0.98047	0.01771	0.26539
Other cardiovascular drugs	0.06215	1.06412	0.02307	0.00706
Cancer	0.28721	1.33271	0.02684	<0.00001
Diuretics	0.23369	1.26325	0.01886	<0.00001
Other circulatory disease	0.05444	1.05595	0.01805	0.00256
Dementia	0.43926	1.55155	0.06041	<0.00001
Other atheroma	0.11958	1.12702	0.09256	0.19637
Antihypertensives	0.06949	1.07197	0.01845	0.00017

Supplementary table S8. Covariate adjustment for THIN.

Propensity score methods versus covariate adjustment – Supplements

Variable	Effect	Hazard ratio	SE	p
Treatment effect	-0.06299	0.93895	0.08072	0.43521
CAD Presentation: Non-ST-elevation myocardial infarction	-0.05035	0.95090	0.01607	0.00173
CAD Presentation: ST-elevation myocardial infarction	0.03913	1.03991	0.05653	0.48876
Diabetes mellitus, no insulin	0.05070	1.05200	0.06548	0.43879
Diabetes mellitus, insulin	0.32932	1.39002	0.07923	0.00003
Age	0.06235	1.06433	0.06471	0.33533
Age squared	0.23228	1.26147	0.07780	0.00283
Procedural Bivalirudin	0.00042	1.00042	0.00012	0.00058
Smoker	-0.05873	0.94297	0.07428	0.42917
Sex: Female	0.13297	1.14222	0.06308	0.03504
Black/African American	0.05507	1.05662	0.07525	0.46425
Hypertension	0.19704	1.21779	0.08374	0.01862
Family history of CAD	-0.06981	0.93257	0.05988	0.24365
Prior PAD	0.07567	1.07861	0.07196	0.29303
Prior CHF	0.12892	1.13759	0.06464	0.04611
Total stent length: 20-40	0.11749	1.12467	0.06176	0.05712
Total stent length: 40+	0.52623	1.69255	0.06583	<0.00001
Stent diameter	-0.11522	0.89117	0.03513	0.00104
Hypercholesterolemia	0.01542	1.01554	0.07680	0.84086
Previous MI	0.25304	1.28794	0.05905	0.00002
eGFR using CKD-EPI	-0.00489	0.99512	0.00118	0.00003
Stent type: 1st generation	-0.02335	0.97692	0.10387	0.82211
Stent type: Bare-metal stent	0.58503	1.79504	0.06772	<0.00001
BMI decile	-0.02441	0.97589	0.00936	0.00915
Hemoglobin	-0.05027	0.95097	0.01411	0.00037
Centre: Utah	0.12211	1.12988	0.13075	0.35036
Centre: Aurora	0.01951	1.01970	0.15640	0.90074
Centre: Pittsburgh	0.41435	1.51339	0.11804	0.00045
Centre: Duke	0.54532	1.72516	0.11807	<0.00001
Centre: Cleveland	0.70408	2.02198	0.12118	<0.00001
Centre: Christiana	-0.05914	0.94258	0.12664	0.64054
Centre: Mount Sinai	-0.10655	0.89893	0.12099	0.37851
Glycoprotein IIb/IIIa	0.05442	1.05593	0.07880	0.48980
Prior Cerebrovascular Disease	0.11190	1.11840	0.07006	0.11023
Previous PCI	-0.03749	0.96321	0.06677	0.57448
Previous CABG	-0.10328	0.90187	0.07088	0.14509

Supplementary table S9. Covariate adjustment for PROMETHEUS.

Stratum	PS boundaries	Number of individuals	Number of events	% events out of total
1	0.00 – 0.27	848	7	0.83%
2	0.27 – 0.31	847	4	0.47%
3	0.31 – 0.34	848	1	0.12%
4	0.34 – 0.37	847	1	0.12%
5	0.37 – 0.40	848	8	0.94%
6	0.40 – 0.44	847	6	0.71%
7	0.44 – 0.48	847	4	0.47%
8	0.48 – 0.54	848	6	0.71%
9	0.54 – 0.61	847	8	0.94%
10	0.61 – 0.93	848	12	1.42%


Supplementary table S10. Propensity score stratification for the ADAPT-DES study with 10 strata.

Only a small percentage of individuals in each stratum experiences an event resulting in as little as 1 event in some strata.

Propensity score methods versus covariate adjustment – Supplements


CHARM

Control: 3,396 individuals (997 all-cause deaths), Beta-blockers: 4,203 individuals (834 all-cause deaths). 18 variables.




CHARM - 1% trimming

Control: 3,396 individuals (997 all-cause deaths), Beta-blockers: 4,203 individuals (834 all-cause deaths). 18 variables.



CHARM - 5% trimming

Control: 3,396 individuals (997 all-cause deaths), Beta-blockers: 4,203 individuals (834 all-cause deaths). 18 variables.




Supplementary figure S10. Comparison of the results for the CHARM study with no trimming (top), 1% trimming (middle) and 5% trimming (bottom).

Propensity score methods versus covariate adjustment – Supplements


ADAPT-DES

No platelet reactivity: 4,930 individuals (20 stent thromboses), Platelet reactivity: 3,650 individuals (36 stent thromboses). 39 variables.




ADAPT-DES - 1% trimming

No platelet reactivity: 4,930 individuals (20 stent thromboses), Platelet reactivity: 3,650 individuals (36 stent thromboses). 39 variables.



ADAPT-DES - 5% trimming

No platelet reactivity: 4,930 individuals (20 stent thromboses), Platelet reactivity: 3,650 individuals (36 stent thromboses). 39 variables.




Supplementary figure S11. Comparison of the results for the ADAPT-DES study with no trimming (top), 1% trimming (middle) and 5% trimming (bottom).

Propensity score methods versus covariate adjustment – Supplements


THIN

Control: 60,921 individuals (13,533 all-cause deaths), Statins: 30,811 individuals (3,763 all-cause deaths). 48 variables.




THIN - 1% trimming

Control: 60,921 individuals (13,533 all-cause deaths), Statins: 30,811 individuals (3,763 all-cause deaths). 48 variables.



THIN - 5% trimming

Control: 60,921 individuals (13,533 all-cause deaths), Statins: 30,811 individuals (3,763 all-cause deaths). 48 variables.




Supplementary figure S12. Comparison of the results for the THIN study with no trimming (top), 1% trimming (middle) and 5% trimming (bottom).

Propensity score methods versus covariate adjustment – Supplements


PROMETHEUS

Clopidogrel: 15,587 individuals (1,368 MACE), Prasugrel: 4,017 individuals (212 MACE). 35 variables.




PROMETHEUS - 1% trimming

Clopidogrel: 15,587 individuals (1,368 MACE), Prasugrel: 4,017 individuals (212 MACE). 35 variables.



PROMETHEUS - 5% trimming

Clopidogrel: 15,587 individuals (1,368 MACE), Prasugrel: 4,017 individuals (212 MACE). 35 variables.



Supplementary figure S13. Comparison of the results for the PROMETHEUS study with no trimming (top), 1% trimming (middle) and 5% trimming (bottom).